Adage Capital Partners
MRTX

Adage Capital Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Adage Capital Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-667,424
Closed -$39.2M – 975
2023
Q4 		$39.2M Sell
667,424
-507,576
-43% -$28.5M 0.08% 252
2023
Q3 		$51.2M Buy
+1,175,000
New +$42M 0.12% 188
2022
Q4 		– Sell
-1,418,747
Closed -$99.1M – 1067
2022
Q3 		$99.1M Buy
+1,418,747
New +$105M 0.25% 94

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Adage Capital Partners's MRTX Position: Q1 2024 in Review

Adage Capital Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 667,424 shares — an estimated $39.2M sold.

Adage Capital Partners first reported a position in MRTX in Q3 2022 and held it in 3 quarters. The position peaked at $99.1M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Adage Capital Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 667,424 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $39.2M.
  • Adage Capital Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Adage Capital Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $99.1M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.